By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roched has entered into an agreement with ChanTest to evaluate the safety of potential drug compounds.

Under the terms of the deal announced today, ChanTest, an ion channel screening provider, will use Roche's xCelligence System RTCA Cardio Instrument and Cellular Dynamics International's iCell Cardiomyocytes to evaluate pharmacological responses to a number of compounds that have been selected based on their known effects on ion channels.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.